カテゴリー： 世界

日本の医薬品開発製造受託機関（CDMO）市場規模、シェア、動向分析レポート、予測2023-2030

【英語タイトル】Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2023-2030

Grand View Researchが出版した調査資料（GVR-4-68039-985-5）・商品コード：GVR-4-68039-985-5
・発行会社（調査会社）：Grand View Research
・発行日：2023年10月
・ページ数：約120
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後8営業日）
・調査対象地域：グローバル
・産業分野：医療・バイオ
◆販売価格オプション（消費税別）
Individual UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Team LicenseUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Enterprise LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

The Japan contract development and manufacturing organization market size was estimated at USD 11.6 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2030. Growing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. There is also increasing investment by various contract development and manufacturing organizations (CDMOs) for facility and service expansion. For instance, in November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform can now develop, manufacture, and introduce cell and gene therapies faster and with greater predictability.

The COVID-19 pandemic significantly affected the industry in Japan. According to the World Health Organization (WHO), by September 2022, 20,488,312 cases of COVID-19 were reported in the country. The COVID-19 pandemic increased the demand for vaccines to prevent the disease in the country. However, despite a rise in the demand for COVID-19 vaccines, the rollout of vaccines was slow compared to other countries. Many CDMOs in Japan expanded their facilities to increase their capacity during the pandemic.

The biopharmaceutical industry’s margins also shrunk due to rising pricing pressure, regulatory challenges, and patent expiration. Contract services were viewed as a “strategic competitive weapon” by biopharmaceutical and pharmaceutical companies because they assisted in overcoming these issues. These services save their customers money. They also helped save time, which could be efficiently utilized in operating and managing a manufacturing & research facility.

Contract manufacturing enables low-cost product development, reducing a product’s overall manufacturing cost. Furthermore, outsourcing services aid in the removal of trade barriers and the entry of firms into foreign markets. Due to these benefits, several companies have chosen to outsource biopharmaceutical manufacturing rather than invest in production equipment and hire skilled labor.

There is a growing demand for biopharmaceutical drugs in Japan to diagnose and treat various chronic diseases. As per the International Trade Administration (ITA), Japan is one of the world’s largest pharmaceutical markets, accounting for USD 109.6 million in 2020, and is actively involved in improving access to biopharmaceutical drugs.

For instance, in June 2021, the Japan Ministry of Health, Labour, and Welfare approved virotherapy teserpaturev for treating patients with malignant glioma. Such approvals are expected to improve access to biopharmaceutical drugs in the country, thereby boosting the demand for manufacturing in the country.

[Key Companies & Market Share Insights]

Some key players are undertaking various strategic initiatives to gain a competitive advantage. Partnerships, new service launches, and expansion are some of the key strategic initiatives adopted by the market players. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to speed the production of adeno-associated viruses for producing drugs for cell and gene therapy. Some prominent players in the Japan contract development and manufacturing organization market include:

CordenPharma International

WuXi AppTec

Cambrex Corporation

Recipharm AB

Lonza

Catalent, Inc.

Laboratory Corporation of America Holdings

Thermo Fisher Scientific, Inc.

Samsung BioLogics

FUJIFILM Corporation

Sumitomo Chemical Company, Limited

CMIC HOLDINGS Co., LTD.

Bushu Pharmaceuticals Ltd.

Nipro Corporation

❖ レポートの目次 ❖

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Workflow
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Workflow
2.2.3. Application
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis
4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
4.3. API
4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Type
4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.4. Antibody drug conjugate (ADC)
4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.5. Others
4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Synthesis
4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.2. Synthetic
4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.3. Solid
4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.4. Liquid
4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.5. Biotech
4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Drug
4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.2. Innovative
4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.3. Generic
4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Manufacturing
4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.2. Continuous manufacturing
4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.3. Batch manufacturing
4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Drug Product
4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Oral solid dose
4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Semi-solid dose
4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Liquid dose
4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Others
4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis
5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Clinical
5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Commercial
5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis
6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Oncology
6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Hormonal
6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Glaucoma
6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Cardiovascular Disease
6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. CORDENPHARMA INTERNATIONAL
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. WuXi AppTec
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Cambrex Corporation
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Recipharm AB
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Lonza
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Catalent, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Laboratory Corporation of America Holdings
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Thermo Fisher Scientific, Inc
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Samsung BioLogics
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. CMIC HOLDINGS Co., LTD
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Bushu Pharmaceuticals LTD.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. NIPRO
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 Japan contract development and manufacturing organization market, by product, 2018 – 2030 (USD Million)
Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 – 2030 (USD Million)
Table 4 Japa contract development and manufacturing organization market, by application, 2018 – 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Japan contract development and manufacturing organization: Market outlook
Fig. 9 Japan contract development and manufacturing organization: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Japan contract development and manufacturing organization market driver impact
Fig. 15 Japan contract development and manufacturing organization market restraint impact
Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
Fig. 19 API market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 20 Type market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 24 Others market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 25 Synthesis market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 26 Synthetic market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 27 Solid market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 28 Liquid market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 29 Biotech market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 30 Drug market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 31 Innovative market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 32 Generic market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 33 Manufacturing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 35 Batch manufacturing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 36 Drug product market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 37 Oral solid dose market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 38 Semi-solid dose market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 39 Liquid dose market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 40 Others market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
Fig. 43 Clinical market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 44 Commercial market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
Fig. 47 Oncology market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 48 Hormonal market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 49 Glaucoma market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 51 Diabetes market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 52 Others market estimates and forecasts, 2018 – 2030 (USD Million)



★調査レポート[日本の医薬品開発製造受託機関（CDMO）市場規模、シェア、動向分析レポート、予測2023-2030] (コード：GVR-4-68039-985-5)販売に関する免責事項を必ずご確認ください。
★調査レポート[日本の医薬品開発製造受託機関（CDMO）市場規模、シェア、動向分析レポート、予測2023-2030]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 細胞＆遺伝子治療CDMO市場-規模、シェア、動向分析レポート、予測2024-2030
  • 人工知能(AI)の世界市場2021-2028：市場規模、シェア、動向分析
  • 標的タンパク質分解市場2020-2030
  • タイの脳健康サプリメント市場 (2024-2030)
  • ガンマブチロラクトンの世界市場2020-2030
  • Interstitial Cystitis Market Insight, Epidemiology and Market Forecast -2030
  • ウイルスベクター製造市場レポート：2030年までの動向、予測、競合分析
  • 世界の自動車用オイルポンプ市場2021-2031
  • 細胞・遺伝子治療製造サービスの世界市場レポート（2024年）
  • Automotive Camera Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

    • ◆H&Iグローバルリサーチのお客様（例）◆